The Impact of Fitness and Dose Intensity on Safety and Efficacy Outcomes after Venetoclax-Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia

被引：0

作者：

Al-Sawaf, Othman ^{[1
,2
,3
]}

Fuerstenau, Moritz ^{[1
,2
,3
]}

Giza, Adam ^{[1
,2
,3
]}

Robrecht, Sandra ^{[1
,2
,3
]}

Von Tresckow, Julia ^{[4
]}

Fink, Anna Maria ^{[1
,2
,3
]}

Simon, Florian ^{[1
,2
,3
]}

Tausch, Eugen ^{[5
]}

Schneider, Christof ^{[6
]}

Sivcheva, Liliya ^{[7
]}

Schwarer, Anthony ^{[8
]}

Loscertales, Javier ^{[9
]}

Weinkove, Robert ^{[10
]}

Strumberg, Dirk ^{[11
]}

Kilfoyle, Allanah R. ^{[12
]}

Juliusson, Gunnar ^{[13
]}

Da Cunha-Bang, Caspar ^{[14
]}

Illmer, Thomas

Gregor, Michael ^{[15
]}

Thornton, Patrick ^{[16
]}

Janssens, Ann ^{[17
]}

Tadmor, Tamar ^{[18
]}

Lindstrom, Vesa ^{[19
,20
]}

Staber, Philipp Bernhard ^{[21
]}

Levin, Mark-David ^{[22
]}

Wendtner, Clemens-Martin ^{[23
]}

Kreuzer, Karl-Anton ^{[1
,2
,3
]}

Ritgen, Matthias ^{[24
]}

Stilgenbauer, Stephan ^{[25
]}

Kater, Arnon P. ^{[26
]}

Niemann, Carsten Utoft ^{[27
]}

Fischer, Kirsten ^{[1
,2
,3
]}

Eichhorst, Barbara F. ^{[28
]}

Hallek, Michael ^{[29
]}

机构：

[1] Univ Cologne, Fac Med, Cologne, Germany

[2] Univ Cologne, Univ Hosp Cologne, Dept Internal Med 1, Ctr Integrated Oncol Aachen Bonn Cologne Duesseld, Cologne, Germany

[3] Univ Cologne, German CLL Study Grp, Cologne, Germany

[4] Univ Duisburg Essen, Univ Hosp Essen, West German Canc Ctr, Clin Hematol & Stem Cell Transplantat, Essen, Germany

[5] Ulm Univ, Div CLL, Dept Internal Med 3, Ulm, Germany

[6] Univ Ulm, Div CLL, Dept Internal Med 3, Ulm, Germany

[7] Multiprofile Hosp Act Treatment HristoBotev, Dept Internal Med 1, Vratsa, Bulgaria

[8] Box Hill Hosp, Melbourne, Vic, Australia

[9] Hosp Univ La Princesa, Madrid, Spain

[10] Wellington Rerenga Ora Blood & Canc Ctr, Capital & Coast Dist Hlth Board, Wellington, New Zealand

[11] Marien Hosp, Herne, Germany

[12] Palmerston North Hosp, Palmerston North, New Zealand

[13] Lund Univ Canc Ctr, Dept Hematol, Lund, Sweden

[14] Rigshosp, Copenhagen, Denmark

[15] Cantonal Hosp Lucerne, Div Hematol, Luzern, Switzerland

[16] Beaumont Hosp, Canc Trials Ireland, Dept Haematol, RCSI, Dublin, Ireland

[17] Univ Hosp Leuven, Leuven, Belgium

[18] Bnai Zion Med Ctr, Hematol, Haifa, Israel

[19] Helsinki Univ Hosp, Dept Hematol, Ctr Comprehens Canc, Helsinki, Finland

[20] Univ Helsinki, Helsinki, Finland

[21] Med Univ Vienna, Div Hematol & Hemostaseol, Dept Med 1, Vienna, Austria

[22] Albert Schweitzer Hosp, Dept Internal Med, Dordrecht, Netherlands

[23] German CLL Study Grp, Munich Clin Schwabing, Dept Hematol Oncol Immunol Palliat Care Infect Di, Munich, Germany

[24] Univ Schleswig Holstein, Dept Internal Med 2, Kiel, Germany

[25] Univ Hosp Ulm, Div CLL, Dept Internal Med 3, Ulm, Germany

[26] Acad Med Ctr, Amsterdam, Netherlands

[27] Copenhagen Univ Hosp, Dept Hematol, Rigshosp, Copenhagen, Denmark

[28] Univ Cologne, Cologne, Germany

[29] Univ Hosp Cologne, Ctr Integrated Oncol Aachen Bonn Cologne Duesseld, Cologne, Germany

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-188827

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：8

共 50 条

[41] Updated Safety and Efficacy Results From a Phase 2 Study of Acalabrutinib, Venetoclax, and Obinutuzumab for Frontline Treatment of Chronic Lymphocytic Leukemia
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (01) : 6 - 7
[42] The Economic Impact of Treatment Sequencing in Chronic Lymphocytic Leukemia in Canada Using Venetoclax plus Obinutuzumab
Guinan, Kimberly
Mathurin, Karine
Lachaine, Jean
Roc, Nancy Paul
Bull, Sarah-Jane
Tankala, Dipti
Barakat, Stephane
Manzoor, Beenish S.
Hillis, Christopher
Banerji, Versha
CANCERS, 2024, 16 (18)
[43] Efficacy and Safety of Tirabrutinib and Idelalisib With or Without Obinutuzumab in Relapsed Chronic Lymphocytic Leukemia
Kutsch, Nadine
Pallasch, Christian
Decker, Thomas
Hebart, Holger
Chow, Kai Uwe
Graeven, Ullrich
Kisro, Jens
Kroeber, Alexander
Tausch, Eugen
Fischer, Kirsten
Fink, Anna-Maria
Wendtner, Clemens-Martin
Ritgen, Matthias
Stilgenbauer, Stephan
Zhang, Danjie
Li, Biao
Jurgensmeier, Juliane M.
Rajakumaraswamy, Nishanthan
Bhargava, Pankaj
Hallek, Michael
Eichhorst, Barbara
HEMASPHERE, 2022, 6 (06):
[44] Long-term follow-up of multicenter phase II trial of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in previously untreated patients with chronic lymphocytic leukemia: impact of early MRD kinetics on posttreatment outcomes
Soumerai, Jacob
Dogan, Ahmet
Seshan, Venkatraman
Flaherty, Kelsey
Carter, Jason
Hochberg, Ephraim
Barnes, Jeffrey
Abramson, Jeremy
Hamilton, Audrey
Noy, Ariela
Owens, Colette
Palomba, M. Lia
Kumar, Anita
Roeker, Lindsey
Thompson, Meghan
Takvorian, Ronald
Epstein-Peterson, Zachary
Geyer, Mark
Ramos-Amador, Walter
Mahajan, Neena
Martignetti, Rosalba
Plummer, Sean
Mi, Joanna
Lynch, Julia
McGree, Brianne
Sherburne, Maryanne
Patterson, Emily
Slupe, Natalie
Chabowska, Maria
Labarre, Alyssa
Choma, Morgan
McCambridge, Grace
Kelly, Hailey
Devlin, Mary
Puccio, Madeline
Garcia, Rayna
Grieve, Clare
Cohen, Aileen
Biondo, Juliana
Jacob, Allison
Abdel-Wahab, Omar
Zelenetz, Andrew
LEUKEMIA & LYMPHOMA, 2023, 64 : S103 - S104
[45] Safety and Efficacy of Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) and Coexisting Medical Conditions: Final Results of the Run-in Phase of the Randomized CLL14 Trial (BO25323)
Fischer, Kirsten
Al-Sawaf, Othman
Fink, Anna-Maria
Dixon, Mark
Bahlo, Jasmin
Warburton, Simon
Kipps, Thomas J.
Weinkove, Robert
Robinson, Sue
Dreyling, Martin H.
Opat, Stephen
Owen, Carolyn J.
Lopez, Javier
Humphrey, Kathryn
Humerickhouse, Rod A.
Tausch, Eugen
Eichhorst, Barbara
Wendtner, Clemens-M.
Langerak, Anton W.
van Dongen, Jacques J. M.
Ritgen, Matthias
Boettcher, Sebastian
Stilgenbauer, Stephan
Goede, Valentin
Mobasher, Mehrdad
Hallek, Michael
BLOOD, 2016, 128 (22)
[46] Clonal Hematopoiesis in Patients with Chronic Lymphocytic Leukemia Treated with Fixed-Duration Venetoclax-Obinutuzumab or Chlorambucil-Obinutuzumab: Insights from the Randomized CLL14 Trial
Al-Sawaf, Othman
Locher, Benjamin N.
Christen, Friederike
Robrecht, Sandra
Zhang, Can
Fink, Anna Maria
Tausch, Eugen
Schneider, Christof
Ritgen, Matthias
Kreuzer, Karl Anton
Fustero, Coral
Hablesreiter, Raphael
Seymour, John F.
Blombery, Piers
Bullinger, Lars
Chyla, Brenda
Jin, Hyun Yong
Jiang, Yanwen
Stilgenbauer, Stephan
Eichhorst, Barbara F.
Hallek, Michael J.
Fischer, Kirsten
Damm, Frederik
BLOOD, 2024, 144 : 4613 - 4615
[47] Phase 2, multicenter GIBB study of obinutuzumab plus bendamustine in previously untreated patients with chronic lymphocytic leukemia
Sharman, Jeff P.
Burke, John M.
Yimer, Habte A.
Boxer, Michael A.
Babu, Sunil
Li, Jia
Mun, Yong
Danilov, Alexey V.
LEUKEMIA & LYMPHOMA, 2021, 62 (04) : 791 - 800
[48] Cost-Effectiveness of Acalabrutinib Monotherapy Compared with Chlorambucil Plus Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia
Munir, Talha
Gaitonde, Priyanka
Waweru, Catherine
BLOOD, 2020, 136
[49] RESULTS OF A PHASE II MULTICENTER STUDY OF OBINUTUZUMAB PLUS BENDAMUSTINE IN PTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA
Danilov, A.
Yimer, H.
Boxer, M.
Di Bella, N.
Babu, S.
Li, J.
Mun, Y.
Skettino, S.
Sharman, J.
HAEMATOLOGICA, 2017, 102 : 71 - 71
[50] EFFECT OF ADHERENCE AND DOSE INTENSITY OF IBRUTINIB ON OUTCOMES IN PATIENTS WITH PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA.
Deisinger, Sara
McNally, Gretchen
Suzuki, Sam
Cole, George
Byrd, John C.
Barr, Paul M.
ONCOLOGY NURSING FORUM, 2016, 43 (02) : 131 - 131

← 1 2 3 4 5 →